title: Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.
abstract: BACKGROUND
  This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients.
  
  
  METHODS
  A clinical pilot study was designed in which patients with ulcer and/or pain at rest were treated with bosentan p.o. at a dose of 62.5 mg twice daily during the first month, which was thereafter up-titrated to 125 mg twice daily. The study endpoints were clinical improvement rate, major or minor amputation rate, haemodynamic changes, changes in endothelial function and angiographic changes.
  
  
  RESULTS
  Seven out of 12 patients were male (58%). Median age was 39 years (range 29-49). The median follow-up was 20 months (range 11-40). All patients were smokers. With bosentan treatment, new ischaemic lesions were observed in only one patient. Overall, clinical improvement was observed in 12 of the 13 extremities (92%). Only two out of 13 extremities underwent amputation (one major and one minor) after bosentan treatment. After being assessed by digital arteriography with subtraction or angio-magnetic resonance imaging, an increase of distal flow was observed in 10 out of the 12 patients. All patients experienced a statistically significant improvement in their BAFMD values (mean: 1.8 at baseline; 6.6 at the end of the treatment; 12.7 three months after the end of the treatment; p < 0.01).
  
  
  CONCLUSIONS
  Bosentan treatment may result in an improvement of clinical, angiographic and endothelial function outcomes. Bosentan should be investigated further in the management of TAO patients. Larger studies are required to confirm these results.
  
  
  BACKGROUND
  ClinicalTrials.gov: NCT01447550.
authors.affiliation: Department of Angiology and Vascular Surgery, Hospital Universitario de Getafe, Madrid, Spain. deharojoaquin@yahoo.es
authors.forename: Joaquin
authors.initials: J
authors.lastname: De Haro
authors.forename: Francisco
authors.initials: F
authors.lastname: Acin
authors.forename: Silvia
authors.initials: S
authors.lastname: Bleda
authors.forename: Cesar
authors.initials: C
authors.lastname: Varela
authors.forename: Leticia
authors.initials: L
authors.lastname: Esparza
mesh_terms: D000328:Adult; D000671:Amputation, Surgical / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D005121:Extremities / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013919:Thromboangiitis Obliterans / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan